Biology and outcome of childhood acute megakaryoblastic leukemia: A single institution's experience

Blood

Volumn 97, Issue 12, 2001, Pages 3727-3732

  Athale, Uma H ^a,b   Razzouk, Bassem I ^a,b   Raimondi, Susana C ^a,b   Long, Xin ^a,b   Behm, Frederick G ^a,b   Head, David R ^a,b   Srivastava, Deo K ^a,b   Rubnitz, Jeffrey E ^a,b   Bowman, Laura ^a,b   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; DOWN SYNDROME; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0035878006     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.12.3727     Document Type: Article

References (43)

1. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460-462.
2. San Miguel JF, Gonzalez M, Canizo MC, et al. Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics. Blood. 1988;72:402-407.
3. Bloomfield CD, Brunning RD. FAB M7: acute megakaryoblastic leukemia-beyond morphology. Ann Intern Med. 1985;103:450-452.
4. Gewirtz AM. Acute megakaryocytic leukemia. Mayo Clin Proc. 1989;64:1447-1451.
5. Ribeiro RC, Oliveira MS, Fairclough D, et al. Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases. Leuk Lymphoma. 1993;10:299-306.
6. Lange BI, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
7. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96:2405-2411.
8. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood. 1992;80:2210-2214.
9. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979-4989.
10. Stevens RF, Hann IM, Wheatley K, et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101:130-140.
11. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood. 1990;75:1932-1940.
12. Zipursky A, Brown E, Christensen H, et al. Leukemia and/or myeloproliferative syndrome in neonates with Down syqdrome. Semin Perinatol. 1997;21:97-101.
13. Zubizarreta P, Felice MS, Alfaro E, et al. Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy. Leuk Res. 1998;22:465-472.
14. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome - a review. Prog Clin Biol Res. 1987;246:33-56.
15. Williams DL, Harris A, Williams KJ, et al. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1984;13:239-257.
16. Testa JR, Misawa S, Oguma N, et al. Chromosomal alterations in acute leukemia patients studied with improved culture methods. Cancer Res. 1985;45:430-434.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
18. Kalwinsky D, Mirro J Jr, Schell M, et al. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide. J Clin Oncol. 1988;6:1134-1143.
19. Dahl GV, Kalwinsky DK, Mirro J Jr, et al. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol. 1990;8:295-303.
20. Hurwitz CA, Krance R, Schell MJ, et al. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992;6(suppl 2):39-43.
21. Arnaout MK, Radomski KM, Srivastava DK, et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages. Leukemia. 2000;14:1736-1742.
22. Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood. 1994;84:1237-1242.
23. Radomski KM, Gandhi V, Sdvastava DK, et al. Interim analysis of cytarabine (ara-C) and cladribine (2-CDA) combination therapy in acute myeloid leukemia [abstract]. Blood. 2000;96:327a.
24. Kaplan EL, Meier P, Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1999;53:457-481.
25. Carroll A, Civin C, Schneider N, et al. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood. 1991;78:748-752.
26. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy In children and younger adults with acute myeloid leukemia: results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311-2318.
27. Pui CH, Rivera G, Mirro J, et al. Acute megakaryoblastic leukemia: blast cell aggregates simulating metastatic tumor. Arch Pathol Lab Med. 1985;109:1033-1035.
28. Cairney AE, McKenna R, Arthur DC, et al. Acute megakaryoblastic leukaemia in children. Br J Haematol. 1986;63:541-554.
29. Slavc I, Urban C, Haas OA, et al. Acute megakaryocytic leukemia in children: clinical, immunologic, and cytogenetic findings in two patients. Cancer. 1991;68:2266-2272.
30. Bevan D, Rose M, Greaves M. Leukaemia of platelet precursors: diverse features in four cases. Br J Haematol. 1982;51:147-164.
31. Sariban E, Oliver C, Corash L, et al. Acute megakaryoblastic leukemia in childhood. Cancer. 1984;54:1423-1428.
32. Behm FG. Diagnosis of childhood acute myeloid leukemia. Clin Lab Med. 1999;19:187-237.
33. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
34. Giles FJ, Koeffler HP. Secondary myelodysplastic syndromes and leukemias. Curr Opin Hematol. 1994;1:256-260.
35. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542-3552.
36. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748-1757.
37. Pagano L, Annino L, Ferrari A, et al. Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1998;100:669-676.
38. Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol. 2000;109:13-23.
39. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569-577.
40. Bhatia S, Neglia JP. Epidemiology of childhood acute myelogenous leukemia. J Pediatr Hematol Oncol. 1995;17:94-100.
41. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630-639.
42. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996;334:1428-1434.
43. Ravindranath Y, Taub JW. Down syndrome and acute myeloid leukemia: lessons learned from experience with high-dose Ara-C containing regimens. Adv Exp Med Biol. 1999;457:409-414.